- Home
- ITIC vs VERV Comparison
ITIC vs VERV Comparison
Compare ITIC & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- VERV
- Stock Information
- Founded
- ITIC 1972
- VERV 2018
- Country
- ITIC United States
- VERV United States
- Employees
- ITIC N/A
- VERV N/A
- Industry
- ITIC Specialty Insurers
- VERV Medicinal Chemicals and Botanical Products
- Sector
- ITIC Finance
- VERV Health Care
- Exchange
- ITIC Nasdaq
- VERV Nasdaq
- Market Cap
- ITIC 404.7M
- VERV 475.0M
- IPO Year
- ITIC N/A
- VERV 2021
- Fundamental
- Price
- ITIC $228.05
- VERV $6.14
- Analyst Decision
- ITIC
- VERV Strong Buy
- Analyst Count
- ITIC 0
- VERV 4
- Target Price
- ITIC N/A
- VERV $25.75
- AVG Volume (30 Days)
- ITIC 12.7K
- VERV 1.5M
- Earning Date
- ITIC 02-11-2025
- VERV 02-25-2025
- Dividend Yield
- ITIC 6.95%
- VERV N/A
- EPS Growth
- ITIC 22.45
- VERV N/A
- EPS
- ITIC 15.10
- VERV N/A
- Revenue
- ITIC $241,018,000.00
- VERV $24,396,000.00
- Revenue This Year
- ITIC N/A
- VERV $97.47
- Revenue Next Year
- ITIC N/A
- VERV N/A
- P/E Ratio
- ITIC $15.10
- VERV N/A
- Revenue Growth
- ITIC 1.93
- VERV 219.91
- 52 Week Low
- ITIC $146.41
- VERV $4.31
- 52 Week High
- ITIC $290.40
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- ITIC 39.00
- VERV 53.75
- Support Level
- ITIC $225.24
- VERV $5.32
- Resistance Level
- ITIC $231.29
- VERV $6.87
- Average True Range (ATR)
- ITIC 6.06
- VERV 0.52
- MACD
- ITIC 0.26
- VERV -0.00
- Stochastic Oscillator
- ITIC 58.01
- VERV 56.74
About ITIC Investors Title Company
Investors Title Co operates primarily in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment primarily issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.